OKYO Pharma Announces Participation in May 2024 Investor Conferences
May 08 2024 - 7:00AM
UK Regulatory
OKYO Pharma Announces Participation in May 2024 Investor
Conferences
LONDON and NEW YORK, May 08, 2024 (GLOBE
NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage
biopharmaceutical company developing innovative ocular therapies
for the treatment of inflammatory dry eye disease (DED), a
multi-billion-dollar market, and anterior ocular segment diseases
including neuropathic corneal pain (NCP), an ocular condition
associated with pain but without an FDA approved therapy, today
announced upcoming presentations at two investor conferences in May
2024.
Conference: Aegis Capital
Virtual Healthcare Conference
Date: Wednesday May 8, 2024, 11 AM EST
Location: Virtual
Presenter: Gary Jacob, PhD, Chief Executive
Officer
Conference: Citizens JMP
Securities Life Sciences Conference
Date: Monday May 13, 2024, 10:30 AM EST
Location: New York, NY
Presenter: Gary Jacob, PhD, Chief Executive
Officer
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical
stage biopharmaceutical company developing innovative therapies for
the treatment of DED and NCP, with ordinary shares listed for
trading on the NASDAQ Capital Market. OKYO is focused on the
discovery and development of novel molecules to treat inflammatory
DED and ocular pain. In addition to the recently completed Phase 2
DED trial, OKYO also has plans underway for the opening of a Phase
2 trial for OK-101 to treat NCP in patients with this debilitating
condition. For further information, please
visit www.okyopharma.com.
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
917-497-7560 |
Business Development & Investor Relations |
Paul Spencer |
+44 (0)20 7495 2379
|
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Sep 2023 to Sep 2024